Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

INTRODUCTION: This 28-week, phase IIIb study assessed safety and maintenance of response to certolizumab pegol (CZP) in a diverse population of rheumatoid arthritis (RA) patients, stratified by prior anti-TNF exposure, concomitant methotrexate (MTX) use and disease duration. The ability to predict a...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinblatt, Michael E., Fleischmann, Roy, van Vollenhoven, Ronald F., Emery, Paul, Huizinga, Tom WJ, Cutolo, Maurizio, van der Heijde, Désirée, Duncan, Benjamin, Davies, Owen, Luijtens, Kristel, Dougados, Maxime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644627/
https://www.ncbi.nlm.nih.gov/pubmed/26568428
http://dx.doi.org/10.1186/s13075-015-0841-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644627/
https://www.ncbi.nlm.nih.gov/pubmed/26568428
http://dx.doi.org/10.1186/s13075-015-0841-9

Ejemplares similares